In OSI Pharmaceuticals, Inc. v. Mylan Pharmaceuticals, Inc., C.A. No. 09-185-SLR (D. Del. June 30, 2011), Judge Robinson recently issued an order enjoining an ANDA defendant “from launching its generic drug until the court’s decision issues” because the stipulated post-trial briefing schedule would exceed “what the court estimates to be the expiration of the 30-month stay invoked by operation of the filing of this lawsuit[.]” Id.